Diet-induced dyslipidemia leads to nonalcoholic fatty liver disease and oxidative stress in guinea pigs

Translational Research

Volumn 168, Issue , 2016, Pages 146-160

  Tveden Nyborg, Pernille ^a   Birck, Malene M ^a   Ipsen, David H ^a   Thiessen, Tina ^a   Feldmann, Linda de Bie ^a   Lindblad, Maiken M ^a   Jensen, Henrik E ^a   Lykkesfeldt, Jens ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CHOLESTEROL; DIHYDROBIOPTERIN; FAT; GLYCOGEN; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; N(G),N(G) DIMETHYLARGININE; SUCROSE; TETRAHYDROBIOPTERIN; TRIACYLGLYCEROL; VEGETABLE OIL; VERY LOW DENSITY LIPOPROTEIN; FAT INTAKE;

ADIPOSE TISSUE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BODY COMPOSITION; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EXPERIMENTAL GUINEA PIG; FATTY LIVER; FEMALE; GLUCOSE TOLERANCE; HISTOPATHOLOGY; INSULIN RESISTANCE; LIPID DIET; LIPID VESICLE; LIVER FUNCTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; SPLENOMEGALY; WESTERN DIET; ADVERSE EFFECTS; ANIMAL; BLOOD; COMPLICATION; FAT INTAKE; GLUCOSE TOLERANCE TEST; GUINEA PIG; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PHYSIOLOGY; SPLEEN;

ANIMALS; BODY COMPOSITION; DIETARY FATS; DYSLIPIDEMIAS; FEMALE; GLUCOSE TOLERANCE TEST; GUINEA PIGS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; SPLEEN;

EID: 84973483420     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2015.10.001     Document Type: Article

References (97)

1. 1 Fernandez, M.L., Volek, J.S., Guinea pigs: a suitable animal model to study lipoprotein metabolism, atherosclerosis and inflammation. Nutr Metab 3 (2006), 17–23.
2. 2 Kim, H.J., Kim, H.J., Lee, K.E., et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 164 (2004), 2169–2175.
3. 3 Adams, L.A., Angulo, P., Lindor, K.D., Nonalcoholic fatty liver disease. Can Med Assoc J 172 (2005), 899–905.
4. 4 Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142 (2012), 1592–1609.
5. 5 Ipsen, D.H., Tveden-Nyborg, P., Lykkesfeldt, J., Does vitamin C deficiency promote fatty liver disease development?. Nutrients 6 (2014), 5473–5499.
6. 6 Wattacheril, J., Chalasani, N., Nonalcoholic fatty liver disease (NAFLD): is it really a serious condition?. Hepatology 56 (2012), 1580–1584.
7. 7 Mantena, S., Vaughn, D., Andringa, K., et al. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem J 417 (2009), 183–193.
8. 8 Dhibi, M., Brahmi, F., Mnari, A., et al. The intake of high fat diet with different trans fatty acid levels differentially induces oxidative stress and non alcoholic fatty liver disease (NAFLD) in rats. Nutr Metab, 8, 2011, 65.
9. 9 Morgan, K., Uyuni, A., Nandgiri, G., et al. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 20 (2008), 843–854.
10. 10 Charbonneau, A., Unson, C.G., Lavoie, J.M., High-fat diet-induced hepatic steatosis reduces glucagon receptor content in rat hepatocytes: potential interaction with acute exercise. J Physiol 579 (2007), 255–267.
11. 11 Green, C.J., Hodson, L., The influence of dietary fat on liver fat accumulation. Nutrients 6 (2014), 5018–5033.
12. 12 Begriche, K., Igoudjil, A., Pessayre, D., Fromenty, B., Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6 (2006), 1–28.
13. 13 Pessayre, D., Fromenty, B., NASH: a mitochondrial disease. J Hepatol 42 (2005), 928–940.
14. 14 Utzschneider, K.M., Kahn, S.E., The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 91 (2006), 4753–4761.
15. 15 Bugianesi, E., McCullough, A.J., Marchesini, G., Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42 (2005), 987–1000.
16. 16 Angulo, P., Obesity and nonalcoholic fatty liver disease. Nutr Rev 65 (2007), S57–S63.
17. 17 Sun, K., Kusminski, C.M., Scherer, P.E., Adipose tissue remodeling and obesity. J Clin Invest 121 (2011), 2094–2101.
18. 18 Furukawa, S., Fujita, T., Shimabukuro, M., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114 (2004), 1752–1761.
19. 19 Odegaard, J.I., Chawla, A., Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 339 (2013), 172–177.
20. 20 Lieber, C.S., Leo, M.A., Mak, K.M., et al. Model of nonalcoholic steatohepatitis. Am J Clin Nutr 79 (2004), 502–509.
21. 21 Kennedy, A.J., Ellacott, K.L., King, V.L., Hasty, A.H., Mouse models of the metabolic syndrome. Dis Model Mech 3 (2010), 156–166.
22. 22 Buettner, R., Schölmerich, J., Bollheimer, L.C., High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity 15 (2007), 798–808.
23. 23 Ouyang, X., Cirillo, P., Sautin, Y., et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 48 (2008), 993–999.
24. 24 Sánchez-Lozada, L., Mu, W., Roncal, C., et al. Comparison of free fructose and glucose to sucrose in the ability to cause fatty liver. Eur J Nutr 49 (2010), 1–9.
25. 25 Birck, M.M., Tveden-Nyborg, P., Lindblad, M.M., Lykkesfeldt, J., Non-terminal blood sampling techniques in guinea pigs. J Vis Exp(92), 2014, e51982.
26. 26 Lee, R.G., Kelley, K.L., Sawyer, J.K., et al. Plasma cholesteryl esters provided by lecithin: cholesterol acyltransferase and acyl-coenzyme a: cholesterol acyltransferase 2 have opposite atherosclerotic potential. Circ Res 95 (2004), 998–1004.
27. 27 Lykkesfeldt, J., Malondialdehyde as biomarker of oxidative damage to lipids caused by smoking. Clin Chim Acta 380 (2007), 50–58.
28. 28 Mortensen, A., Lykkesfeldt, J., Kinetics of acid-induced degradation of tetra- and dihydrobiopterin in relation to their relevance as biomarkers of endothelial function. Biomarkers 18 (2013), 55–62.
29. 29 Lykkesfeldt, J., Determination of malondialdehyde as dithiobarbituric acid adduct in biological samples by HPLC with fluorescence detection: comparison with ultraviolet-visible spectrophotometry. Clin Chem 47 (2001), 1725–1727.
30. 30 Tcherkas, Y.V., Kartsova, L.A., Krasnova, I.N., Analysis of amino acids in human serum by isocratic reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr A 913 (2001), 303–308.
31. 31 Zhang, W.Z., Kaye, D.M., Simultaneous determination of arginine and seven metabolites in plasma by reversed-phase liquid chromatography with a time-controlled ortho-phthaldialdehyde precolumn derivatization. Anal Biochem 326 (2004), 87–92.
32. 32 Lykkesfeldt, J., Determination of ascorbic acid and dehydroascorbic acid in biological samples by high-performance liquid chromatography using subtraction methods: reliable reduction with tris[2-carboxyethyl]phosphine hydrochloride. Anal Biochem 282 (2000), 89–93.
33. 33 Lykkesfeldt, J., Measurement of ascorbic acid and dehydroascorbic acid in biological samples. Maines, M., Costa, L.G., Hodson, E., Reed, J.C., (eds.) Current protocols in toxicology, 2002, John Wiley & Sons, New York, 7.6.1–7.6.15.
34. 34 Lykkesfeldt, J., Ascorbate and dehydroascorbic acid as reliable biomarkers of oxidative stress: analytical reproducibility and long-term stability of plasma samples subjected to acidic deproteinization. Cancer Epidemiol Biomarkers Prev 16 (2007), 2513–2516.
35. 35 Hissin, P.J., Hilf, R., Fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74 (1976), 214–226.
36. 36 Sogaard, D., Lindblad, M.M., Paidi, M.D., et al. In vivo vitamin C deficiency in guinea pigs increases ascorbate transporters in liver but not kidney and brain. Nutr Res 34 (2014), 639–645.
37. 37 Brunt, E.M., Kleiner, D.E., Wilson, L.A., et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53 (2011), 810–820.
38. 38 Kleiner, D.E., Brunt, E.M., Van Natta, M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
39. 39 Lloyd, D.J., McCormick, J., Helmering, J., et al. Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48−/− Lepob/ob mice devoid of ApoE or Ldlr. Am J Physiol Endocrinol Metab 294 (2008), E496–E505.
40. 40 Ye, P., Cheah, I.K., Halliwell, B., A high-fat and cholesterol diet causes fatty liver in guinea pigs. The role of iron and oxidative damage. Free Radic Res 47 (2013), 602–613.
41. 41 Rolo, A.P., Teodoro, J.S., Palmeira, C.M., Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 52 (2012), 59–69.
42. 42 Browning, J.D., Horton, J.D., Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114 (2004), 147–152.
43. 43 Xu, Z.-J., Fan, J.-G., Ding, X.-D., Qiao, L., Wang, G.-L., Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Dig Dis Sci 55 (2010), 931–940.
44. 44 Neuschwander-Tetri, B.A., Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52 (2010), 774–788.
45. 45 Clapper, J.R., Hendricks, M.D., Gu, G., et al. Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. Am J Physiol Gastrointest Liver Physiol 305 (2013), G483–G495.
46. 46 Suzuki, K., Kirikoshi, H., Yoneda, M., et al. Measurement of spleen volume is useful for distinguishing between simple steatosis and early-stage non-alcoholic steatohepatitis. Hepatol Res 40 (2010), 693–700.
47. 47 Tsushima, Y., Endo, K., Spleen enlargement in patients with nonalcoholic fatty liver: correlation between degree of fatty infiltration in liver and size of spleen. Dig Dis Sci 45 (2000), 196–200.
48. 48 Altunkaynak, B.Z., Ozbek, E., Altunkaynak, M.E., A stereological and histological analysis of spleen on obese female rats, fed with high fat diet. Saudi Med J 28 (2007), 353–357.
49. 49 Frikke-Schmidt, H., Tveden-Nyborg, P., Birck, M.M., Lykkesfeldt, J., High dietary fat and cholesterol exacerbates chronic vitamin C deficiency in guinea pigs. Br J Nutr 105 (2011), 54–61.
50. 50 Ha, T.Y., Otsuka, M., Arakawa, N., Ascorbate indirectly stimulates fatty acid utilization in primary cultured guinea pig hepatocytes by enhancing carnitine synthesis. J Nutr 124 (1994), 732–737.
51. 51 Rebouche, C.J., Ascorbic-acid and carnitine biosynthesis. Am J Clin Nutr 54 (1991), S1147–S1152.
52. 52 Lykkesfeldt, J., Increased oxidative damage in vitamin C deficiency is accompanied by induction of ascorbic acid recycling capacity in young but not mature guinea pigs. Free Radic Res 36 (2002), 567–574.
53. 53 Lykkesfeldt, J., Trueba, G.P., Poulsen, H.E., Christen, S., Vitamin C deficiency in weanling guinea pigs: differential expression of oxidative stress and DNA repair in liver and brain. Br J Nutr 98 (2007), 1116–1119.
54. 54 Jaeschke, H., Gores, G.J., Cederbaum, A.I., et al. Mechanisms of hepatotoxicity. Toxicol Sci 65 (2002), 166–176.
55. 55 Caldwell, S.H., Swerdlow, R.H., Khan, E.M., et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 31 (1999), 430–434.
56. 56 Ibdah, J.A., Perlegas, P., Zhao, Y., et al. Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. Gastroenterology 128 (2005), 1381–1390.
57. 57 Perez-Carreras, M., Del Hoyo, P., Martin, M.A., et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 38 (2003), 999–1007.
58. 58 Uchiyama, S., Shimizu, T., Shirasawa, T., CuZn-SOD deficiency causes ApoB degradation and induces hepatic lipid accumulation by impaired lipoprotein secretion in mice. J Biol Chem 281 (2006), 31713–31719.
59. 59 Yang, Y.Y., Lee, T.Y., Huang, Y.T., et al. Asymmetric dimethylarginine (ADMA) determines the improvement of hepatic endothelial dysfunction by vitamin E in cirrhotic rats. Liver Int 32 (2012), 48–57.
60. 60 Van de Casteele, M., Van Pelt, J.F., Nevens, F., Fevery, J., Reichen, J., Low NO bioavailability in CCl4 cirrhotic rat livers might result from low NO synthesis combined with decreased superoxide dismutase activity allowing superoxide-mediated NO breakdown: a comparison of two portal hypertensive rat models with healthy controls. Comp Hepatol, 2, 2003, 2.
61. 61 Vizzutti, F., Romanelli, R.G., Arena, U., et al. ADMA correlates with portal pressure in patients with compensated cirrhosis. Eur J Clin Invest 37 (2007), 509–515.
62. 62 Bosch, J., Abraldes, J.G., Fernandez, M., Garcia-Pagan, J.C., Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol 53 (2010), 558–567.
63. 63 Vallance, P., Leone, A., Calver, A., Collier, J., Moncada, S., Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992), 572–575.
64. 64 Leiper, J., Nandi, M., Torondel, B., et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 13 (2007), 198–203.
65. 65 Laleman, W., Omasta, A., Van de Casteele, M., et al. A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology 42 (2005), 1382–1390.
66. 66 Mookerjee, R.P., Mehta, G., Balasubramaniyan, V., et al. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. J Hepatol 62 (2015), 325–331.
67. 67 Dogru, T., Genc, H., Tapan, S., et al. Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease?. Diabetes Res Clin Pract 96 (2012), 47–52.
68. 68 Lluch, P., Torondel, B., Medina, P., et al. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol 41 (2004), 55–59.
69. 69 Mookerjee, R.P., Malaki, M., Davies, N.A., et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology 45 (2007), 62–71.
70. 70 Ha, S.-K., Chae, C., Inducible nitric oxide distribution in the fatty liver of a mouse with high fat diet-induced obesity. Exp Anim 59 (2010), 595–604.
71. 71 McNaughton, L., Puttagunta, L., Martinez-Cuesta, M.A., et al. Distribution of nitric oxide synthase in normal and cirrhotic human liver. Proc Natl Acad Sci U S A 99 (2002), 17161–17166.
72. 72 Diesen, D.L., Kuo, P.C., Nitric oxide and redox regulation in the liver: part I. General considerations and redox biology in hepatitis. J Surg Res 162 (2010), 95–109.
73. 73 Gow, A.J., Ischiropoulos, H., Nitric oxide chemistry and cellular signaling. J Cell Physiol 187 (2001), 277–282.
74. 74 Vallance, P., Leiper, J., Blocking NO synthesis: how, where and why?. Nat Rev Drug Discov 1 (2002), 939–950.
75. 75 Matei, V., Rodriguez-Vilarrupla, A., Deulofeu, R., et al. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology 44 (2006), 44–52.
76. 76 Heitzer, T., Krohn, K., Albers, S., Meinertz, T., Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus. Diabetologia 43 (2000), 1435–1438.
77. 77 Wang, X., Hattori, Y., Satoh, H., et al. Tetrahydrobiopterin prevents endothelial dysfunction and restores adiponectin levels in rats. Eur J Pharmacol 555 (2007), 48–53.
78. 78 Elrod, J.W., Duranski, M.R., Langston, W., et al. eNOS gene therapy exacerbates hepatic ischemia-reperfusion injury in diabetes: a role for eNOS uncoupling. Circ Res 99 (2006), 78–85.
79. 79 Mortensen, A., Lykkesfeldt, J., Does vitamin C enhance nitric oxide bioavailability in a tetrahydrobiopterin-dependent manner? In vitro, in vivo and clinical studies. Nitric Oxide 36 (2014), 51–57.
80. 80 Lin, E.C., Fernandez, M.L., Tosca, M.A., McNamara, D.J., Regulation of hepatic LDL metabolism in the guinea pig by dietary fat and cholesterol. J Lipid Res 35 (1994), 446–457.
81. 81 Sun, D., Fernandez, M.L., Lin, E.C., McNamara, D.J., Regulation of guinea pig hepatic acyl-coa: cholesterol acyltransferase activity by dietary fat saturation and cholesterol. J Nutr Biochem 10 (1999), 172–180.
82. 82 Torres-Gonzalez, M., Shrestha, S., Sharman, M., et al. Carbohydrate restriction alters hepatic cholesterol metabolism in guinea pigs fed a hypercholesterolemic diet. J Nutr 137 (2007), 2219–2223.
83. 83 Min, H.K., Kapoor, A., Fuchs, M., et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 15 (2012), 665–674.
84. 84 Chatrath, H., Vuppalanchi, R., Chalasani, N., Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis 32 (2012), 22–29.
85. 85 Speliotes, E.K., Massaro, J.M., Hoffmann, U., et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 51 (2010), 1979–1987.
86. 86 Anderssohn, M., Rosenberg, M., Schwedhelm, E., et al. The L-Arginine-asymmetric dimethylarginine ratio is an independent predictor of mortality in dilated cardiomyopathy. J Card Fail 18 (2012), 904–911.
87. 87 Loland, K.H., Bleie, O., Borgeraas, H., et al. The association between progression of atherosclerosis and the methylated amino acids asymmetric dimethylarginine and trimethyllysine. PLoS One, 8, 2013, e64774.
88. 88 Sharman, M.J., Fernandez, M.L., Zern, T.L., et al. Replacing dietary carbohydrate with protein and fat decreases the concentrations of small LDL and the inflammatory response induced by atherogenic diets in the guinea pig. J Nutr Biochem 19 (2008), 732–738.
89. 89 Leite, J.O., DeOgburn, R., Ratliff, J., et al. Low-carbohydrate diets reduce lipid accumulation and arterial inflammation in guinea pigs fed a high-cholesterol diet. Atherosclerosis 209 (2010), 442–448.
90. 90 Cos, E., Ramjiganesh, T., Roy, S., et al. Soluble fiber and soybean protein reduce atherosclerotic lesions in guinea pigs. Sex and hormonal status determine lesion extension. Lipids 36 (2001), 1209–1216.
91. 91 Ye, P., Cheah, I.K., Halliwell, B., High fat diets and pathology in the guinea pig. Atherosclerosis or liver damage?. Biochim Biophys Acta 1832 (2013), 355–364.
92. 92 deOgburn, R., Leite, J.O., Ratliff, J., et al. Effects of increased dietary cholesterol with carbohydrate restriction on hepatic lipid metabolism in guinea pigs. Comp Med 62 (2012), 109–115.
93. 93 Kainuma, M., Fujimoto, M., Sekiya, N., et al. Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol 41 (2006), 971–980.
94. 94 Roy, S., Vega-Lopez, S., Fernandez, M.L., Gender and hormonal status affect the hypolipidemic mechanisms of dietary soluble fiber in guinea pigs. J Nutr 130 (2000), 600–607.
95. 95 Fernandez, M.L., West, K.L., Roy, S., Ramjiganesh, T., Dietary fat saturation and gender/hormonal status modulate plasma lipids and lipoprotein composition. J Nutr Biochem 12 (2001), 703–710.
96. 96 de Castro, U., Dos Santos, R., Silva, M.E., et al. Age-dependent effect of high-fructose and high-fat diets on lipid metabolism and lipid accumulation in liver and kidney of rats. Lipids Health Dis, 12, 2013, 136.
97. 97 Lemonnier, D., Effect of age, sex, and site on the cellularity of the adipose tissue in mice and rats rendered obese by a high-fat diet. J Clin Invest, 51, 1972, 2907.